Acadian Asset Management’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-151,630
| Closed | -$1.12M | – | 2114 |
|
|
2026
Q1 | $1.12M | Buy |
151,630
+26,259
| +21% | +$171K | ﹤0.01% | 1122 |
|
|
2025
Q4 | $787K | Sell |
125,371
-8,154
| -6% | -$47.6K | ﹤0.01% | 1179 |
|
|
2025
Q3 | $519K | Hold |
133,525
| – | – | ﹤0.01% | 1205 |
|
|
2025
Q2 | $610K | Hold |
133,525
| – | – | ﹤0.01% | 1097 |
|
|
2025
Q1 | $650K | Sell |
133,525
-12,141
| -8% | -$73.7K | ﹤0.01% | 1022 |
|
|
2024
Q4 | $977K | Sell |
145,666
-12,046
| -8% | -$89.7K | ﹤0.01% | 932 |
|
|
2024
Q3 | $1.22M | Sell |
157,712
-27,807
| -15% | -$168K | ﹤0.01% | 871 |
|
|
2024
Q2 | $1.11M | Buy |
185,519
+6,435
| +4% | +$48.9K | ﹤0.01% | 961 |
|
|
2024
Q1 | $1.61M | Buy |
179,084
+53,420
| +43% | +$487K | 0.01% | 710 |
|
|
2023
Q4 | $1.19M | Buy |
125,664
+42,495
| +51% | +$374K | ﹤0.01% | 811 |
|
|
2023
Q3 | $988K | Buy |
83,169
+53,376
| +179% | +$946K | ﹤0.01% | 855 |
|
|
2023
Q2 | $729K | Buy |
29,793
+28,341
| +1,952% | +$738K | ﹤0.01% | 960 |
|
|
2023
Q1 | $45K | Buy |
+1,452
| New | +$84K | ﹤0.01% | 1529 |
|
|
2022
Q3 | – | Sell |
-8,458
| Closed | -$700K | – | 1759 |
|
|
2022
Q2 | $700K | Buy |
+8,458
| New | +$746K | ﹤0.01% | 893 |
|
|
2022
Q1 | – | Sell |
-25,895
| Closed | -$4.33M | – | 1719 |
|
|
2021
Q4 | $4.33M | Sell |
25,895
-8,445
| -25% | -$953K | 0.02% | 483 |
|
|
2021
Q3 | $2.96M | Buy |
34,340
+684
| +2% | +$45.3K | 0.01% | 581 |
|
|
2021
Q2 | $1.83M | Hold |
33,656
| – | – | 0.01% | 732 |
|
|
2021
Q1 | $2.01M | Buy |
33,656
+977
| +3% | +$57.1K | 0.01% | 737 |
|
|
2020
Q4 | $1.71M | Buy |
32,679
+3,592
| +12% | +$200K | 0.01% | 808 |
|
|
2020
Q3 | $1.41M | Buy |
29,087
+7,347
| +34% | +$351K | 0.01% | 775 |
|
|
2020
Q2 | $1.13M | Buy |
21,740
+5,851
| +37% | +$295K | ﹤0.01% | 921 |
|
|
2020
Q1 | $693K | Buy |
15,889
+3,722
| +31% | +$151K | ﹤0.01% | 896 |
|
|
2019
Q4 | $488K | Buy |
12,167
+6,870
| +130% | +$211K | ﹤0.01% | 1078 |
|
|
2019
Q3 | $174K | Buy |
5,297
+3,914
| +283% | +$189K | ﹤0.01% | 1352 |
|
|
2019
Q2 | $107K | Buy |
+1,383
| New | +$215K | ﹤0.01% | 1361 |
|
Acadian Asset Management's KZR Position: Q2 2026 in Review
Acadian Asset Management sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 151,630 shares — an estimated $1.12M sold.
Acadian Asset Management first reported a position in KZR in Q2 2019 and held it in 25 quarters. The position peaked at $4.33M in Q4 2021. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Acadian Asset Management reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Acadian Asset Management sold 151,630 Kezar Life Sciences shares in Q2 2026, an estimated $1.12M.
- Acadian Asset Management first reported a position in Kezar Life Sciences in Q2 2019 and held it in 25 quarters.
- Acadian Asset Management's Kezar Life Sciences position peaked at $4.33M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.